A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma

3Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

The network meta-analysis was conducted to compare the short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma (RCC). We initially searched databases for randomized controlled trials (RCTs) on different single-drug targeted therapies in treating RCC. The meta-analysis combined the direct and indirect evidence to calculate the pooled odds ratios (OR) and draw surface under the cumulative ranking curves (SUCRA). A total of 14 eligible RCTs were ultimately selected. The partial response (PR) of Cabozantinib in the treatment of RCC was better than Sunitinib (OR = 2.7, 95%CI = 1.0-7.8), Everolimus (OR = 8.1, 95%CI = 3.1-25.0), and Temsirolimus (OR = 4.8, 95%CI = 1.0-31.0); the overall response rate (ORR) of Cabozantinib was better than Sorafenib, Sunitinib, Everolimus, and Temsirolimus (OR = 5.5, 95%CI = 1.1-27.0; OR = 2.6, 95%CI = 1.1-6.6; OR = 8.3, 95%CI = 3.5-20.0; OR = 5.7, 95%CI = 1.3-28.0 respectively). In addition, as for complete response (CR), PR, stable disease (SD), progressive disease (PD), ORR, and disease control rate (DCR), Cabozantinib had the best short-term efficacy among nine single-drug targeted therapies in the treatment of RCC (CR: 50.3%; PR: 93.6%; SD: 75.1%; PD: 68.0%; ORR: 95.5%; DCR: 73.2%); while Everolimus had the worst short-term efficacy (CR: 33.6%; PR: 22.3%; SD: 78.0%; PD: 35.9%; ORR: 22.9%; DCR: 19.9%). Our network meta-analysis indicated that Cabozantinib might have better short-term efficacy than other regimens in the treatment of RCC, while Everolimus might have poor short-term efficacy.

References Powered by Scopus

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

25682Citations
N/AReaders
Get full text

Cancer statistics, 2015

12203Citations
N/AReaders
Get full text

The biology of VEGF and its receptors

8453Citations
N/AReaders
Get full text

Cited by Powered by Scopus

First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis

7Citations
N/AReaders
Get full text

Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

He, H. L., & Yao, W. X. (2017). A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma. Bioscience Reports, 37(6). https://doi.org/10.1042/BSR20170827

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

50%

Researcher 4

33%

Lecturer / Post doc 2

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

50%

Pharmacology, Toxicology and Pharmaceut... 5

31%

Environmental Science 2

13%

Nursing and Health Professions 1

6%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 21

Save time finding and organizing research with Mendeley

Sign up for free